TABLE 3.

Medication Data, Disease Activity, MARS-5, and CPSS

Characteristic	Result
IBD medication class*
Oral 5-ASA, n (%)	31 (27.6)
Rectal 5-ASA, n (%)	10 (8.9)
Adalimumab s.c., n (%)	24 (21.4)
Infusion biologic, n (%)	41 (36.6)
Thiopurine, n (%)	47 (41.9)
Methotrexate, n (%)	4 (3.5)
Budesonide, n (%)	4 (3.5)
Oral steroid, n (%)	12 (10.7)
Antibiotic, n (%)	4 (3.5)
IBDSI score, mean (SD)†	15.5 (9.2)
MARS-5 score, mean (SD)	22.5 (2.2)
MARS-5 week 0, mean (SD)	22.3 (2.5)
MARS-5 week 52, mean (SD)	22.7 (2.5)
MARS-5 <20, n (%)	12 (10.7)
Monitoring adherence < 90%, n (%)‡	20 (17.9)
CPSS score, mean (SD)†	5.9 (2.7)

5-ASA indicates 5-aminosalicylate.

*Number of patients taking class of medication at any time throughout study period (1 year).

^†Mean over study period (1 year).

^‡Number of patients reporting nonadherence (<90%) over study period (1 year).

s.c., subcutaneous.